Repurposing existing medications for antineoplastic purposes can provide a safe, cost-effective, and efficacious means to further augment available cancer care. Clinical and preclinical studies suggest a role for the ßadrenergic antagonist (ß-blocker) propranolol in reducing rates of tumor progression in both solid and hematologic malignancies. | Repurposing existing medications as cancer therapy Design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation
